These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27545696)

  • 1. A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity.
    Millner AH; Tiefenbacher S; Robinson M; Boesen HT
    Int J Lab Hematol; 2016 Dec; 38(6):639-647. PubMed ID: 27545696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
    Kershaw GW; Chen LS; Jayakodi D; Dunkley SM
    Thromb Res; 2013; 132(6):735-41. PubMed ID: 24119613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rapid Bethesda assay is equivalent to the standard Bethesda assay for detection of factor IX inhibitors in patients with severe haemophilia B.
    Sahud M; Zhukov O; Naides SJ; Serrano C; Wong E; Dlott J; Racke F
    Haemophilia; 2020 Jul; 26(4):735-740. PubMed ID: 32420682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].
    Feng HM; Li Q; Xu WS; Chen DM; Zheng L
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):592-5. PubMed ID: 27113194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].
    Fan LK; Wang ZW; Hua BL; Su W; Wang SJ; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):551-4. PubMed ID: 19968068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
    Verbruggen B; van Heerde WL; Laros-van Gorkom BA
    Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nijmegen-Bethesda assay to measure factor VIII inhibitors.
    Duncan E; Collecutt M; Street A
    Methods Mol Biol; 2013; 992():321-33. PubMed ID: 23546724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency.
    Gadarowski JJ; Czapek EE; Ontiveros JD; Pedraza JL
    Acta Haematol; 1988; 80(3):134-8. PubMed ID: 3143212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay.
    Kim SY; Kang SY; Lee WI
    Korean J Lab Med; 2010 Jun; 30(3):260-3. PubMed ID: 20603586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center.
    Kershaw G; Jayakodi D; Dunkley S
    Semin Thromb Hemost; 2009 Nov; 35(8):760-8. PubMed ID: 20169512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey.
    Batty P; Riddell A; Kitchen S; Sardo Infirri S; Walker I; Woods T; Jennings I; Hart DP
    Haemophilia; 2021 May; 27(3):490-499. PubMed ID: 33650732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia.
    Favaloro EJ; Bonar R; Kershaw G; Mohammed S; Duncan E; Marsden K;
    Haemophilia; 2010 Jul; 16(4):662-70. PubMed ID: 20070382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of lupus anticoagulants in immediate acting inhibitor positivity in congenital haemophilia A patients.
    Patil R; S C; Parihar A; Mohite A; Shetty S
    Thromb Res; 2018 Dec; 172():29-35. PubMed ID: 30359788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa: a preliminary study.
    Balôgôg PN; Tagny CT; Ndoumba A; Mbanya D
    Int J Lab Hematol; 2014 Oct; 36(5):566-70. PubMed ID: 25356499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory identification of factor inhibitors: an update.
    Kershaw G; Favaloro EJ
    Pathology; 2012 Jun; 44(4):293-302. PubMed ID: 22531341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
    Ezban M; Hermit MB; Persson E
    Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
    Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
    Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.
    Miller CH; Boylan B; Shapiro AD; Lentz SR; Wicklund BM;
    J Thromb Haemost; 2017 Oct; 15(10):1971-1976. PubMed ID: 28795528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation.
    Meijer P; Verbruggen B
    Semin Thromb Hemost; 2009 Nov; 35(8):786-93. PubMed ID: 20169515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.